46. Malignant rheumatoid arthritis Clinical trials / Disease details
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2009-016055-22-SE (EUCTR) | 09/03/2011 | 11/01/2011 | Hepatitis A vaccine in patients with immunomodulative drugs | Hepatitis A vaccine in patients with immunomodulative drugs | Patients with rheumatoid arthritis treated with immunosuppressive medication MedDRA version: 12.1;Level: LLT;Classification code 10039073;Term: Rheumatoid arthritis MedDRA version: 12.1;Classification code 10054980;Term: Immunosuppressant drug therapy MedDRA version: 12.1;Classification code 10063430;Term: Hepatitis A immunisation | Trade Name: Epaxal Product Name: Epaxal Other descriptive name: Inactivated hepatitis A virus Trade Name: Havrix Product Name: Havrix Other descriptive name: inactivated hepatitis A virus | HY, HUS | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 380 | Finland;Sweden | |||
| 2 | NCT01360970 (ClinicalTrials.gov) | September 2009 | 24/5/2011 | Hepatitis A Vaccine in Patients With Immunomodulating Drugs | Hepatitis A Vaccination in Patients With Rheumatoid Arthritis Treated With TNF-inhibitors and/or Methotrexate | Response to Hepatitis A Vaccine | Biological: hepatitis A vaccine ( HAVRIX or EPAXAL) | Lars Rombo | NULL | Completed | 18 Years | N/A | Both | 68 | Phase 2 | Finland;Sweden |